Professional indemnity insurance for APNA members to 31 March 2019 for $9.17 per month
HbA1C Reduction and Reduced Distress with Structure Self Monitored Blood Glucose
The growing prevalence of diabetes in the Australian community places an increasing demand on general practice to provide optimal support to people with diabetes. Several US and European studies have demonstrated the benefits of structured self-monitoring of blood glucose (SMBG). In the local context, the Structured Testing Program Implementation (STeP IT UP) trial assessed the impact of structured SMBG on HbA1c and diabetes-related distress in individuals with non-insulin treated type 2 diabetes managed in clinical settings across Australia. By sharing the findings of this trial, this session will aim to equip you with best practice and clinically-validated tools to help you better support your patients with diabetes.
Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 35 years, the Accu-Chek brand has been dedicated to enable people with diabetes to live life as normal and active as possible as well as to empower healthcare professionals to manage their patients’ condition in an optimal way. Today, the Accu-Chek portfolio offers people with diabetes and healthcare professionals innovative products and impactful solutions for convenient, efficient and effective diabetes management spanning from blood glucose monitoring through information management to insulin delivery. The Accu-Chek brand encompasses blood glucose meters, insulin delivery systems, lancing devices, data management systems and education programs, leading to an improved medical outcome.
Presented by Professor Jane Speight and Dr Hilton Shapiro